NasdaqGS:ADPTLife Sciences
The Bull Case For Adaptive Biotechnologies (ADPT) Could Change Following New Pfizer Immune-Data Deals And Spinout Financing – Learn Why
Adaptive Biotechnologies recently announced that its subsidiary Digital Biotechnologies, Inc. began a Series A Preferred Stock round targeting up to US$15,000,000 while retaining nearly half ownership, and entered two non-exclusive T-cell receptor discovery and immune data licensing agreements with Pfizer that could yield up to US$890,000,000 in milestone payments.
An additional detail for investors is that these Pfizer agreements deepen Adaptive’s role in immune-driven drug development...